Walpar Nutritions Limited (NSE:WALPAR)

India · Delayed Price · Currency is INR

33.60

-1.75 (-4.95%)

At close: Jul 8, 2026

-29.04% (1Y)

Market Cap	315.52M -47.2%
Revenue (ttm)	757.46M +17.7%
Net Income	23.31M -5.7%
EPS	2.49 -6.5%
Shares Out	9.39M
PE Ratio	13.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,000
Open	35.50
Previous Close	35.35
Day's Range	33.60 - 35.50
52-Week Range	21.25 - 51.50
Beta	-0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Walpar Nutritions

Walpar Nutritions Limited manufactures and trades pharmaceutical, nutraceutical, herbal, and ayurvedic commodities in India. The company offers G-Flora, a probiotic blend for gut health and immunity; Inosia-F, an inositol supplement; Inovam Plus, a multivitamin; Ironica-CR, controlled-release iron supplement; Myobest, muscle support formula; Ovality, ovarian health support; Ovanyx-F, a female reproductive health supplement; Ovacon-F, women's fertility support; PCOS Care Forte, a PCOS support; Procive-F, female fertility enhancement supplement; ... [Read more]

Industry Pharmaceutical Preparations

Founded 2009

Country India

Stock Exchange National Stock Exchange of India

Ticker Symbol WALPAR

Full Company Profile

Financial Performance

In fiscal year 2025, Walpar Nutritions's revenue was 719.60 million, an increase of 14.93% compared to the previous year's 626.13 million. Earnings were 23.24 million, an increase of 46.92%.

Financial Statements